vs
ASP Isotopes Inc.（ASPI）与TriSalus Life Sciences, Inc.（TLSI）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是TriSalus Life Sciences, Inc.的1.3倍（$16.7M vs $13.2M），ASP Isotopes Inc.同比增速更快（1295.7% vs 59.8%），TriSalus Life Sciences, Inc.自由现金流更多（$-2.5M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
TriSalus生命科学公司是一家临床阶段生物技术企业，专注于免疫肿瘤学与介入肿瘤学领域，研发专有的靶向给药技术，用于提升肝脏、胰腺等难治性实体瘤患者的治疗效果，主要在北美市场开展临床合作及业务运营。
ASPI vs TLSI — 直观对比
营收规模更大
ASPI
是对方的1.3倍
$13.2M
营收增速更快
ASPI
高出1235.8%
59.8%
自由现金流更多
TLSI
多$44.9M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $13.2M |
| 净利润 | — | $-9.8M |
| 毛利率 | 12.5% | 86.7% |
| 营业利润率 | — | -24.8% |
| 净利率 | — | -73.9% |
| 营收同比 | 1295.7% | 59.8% |
| 净利润同比 | -586.8% | 3.5% |
| 每股收益（稀释后） | — | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPITLSI
| Q4 25 | $16.7M | $13.2M | ||
| Q3 25 | $4.9M | $11.6M | ||
| Q2 25 | — | $11.2M | ||
| Q1 25 | — | $9.2M | ||
| Q4 24 | — | $8.3M | ||
| Q3 24 | — | $7.3M | ||
| Q2 24 | — | $7.4M | ||
| Q1 24 | — | $6.5M |
净利润ASPITLSI
| Q4 25 | — | $-9.8M | ||
| Q3 25 | $-12.9M | $-10.8M | ||
| Q2 25 | — | $-8.3M | ||
| Q1 25 | — | $-10.4M | ||
| Q4 24 | — | $-10.1M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $-13.2M |
毛利率ASPITLSI
| Q4 25 | 12.5% | 86.7% | ||
| Q3 25 | 8.7% | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
营业利润率ASPITLSI
| Q4 25 | — | -24.8% | ||
| Q3 25 | -306.1% | -77.9% | ||
| Q2 25 | — | -65.4% | ||
| Q1 25 | — | -79.9% | ||
| Q4 24 | — | -91.8% | ||
| Q3 24 | — | -118.9% | ||
| Q2 24 | — | -111.0% | ||
| Q1 24 | — | -180.8% |
净利率ASPITLSI
| Q4 25 | — | -73.9% | ||
| Q3 25 | -263.7% | -93.5% | ||
| Q2 25 | — | -73.9% | ||
| Q1 25 | — | -113.2% | ||
| Q4 24 | — | -122.4% | ||
| Q3 24 | — | -32.6% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -204.5% |
每股收益（稀释后）ASPITLSI
| Q4 25 | — | $-0.22 | ||
| Q3 25 | $-0.15 | $-0.96 | ||
| Q2 25 | — | $-0.27 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | — | $-0.38 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | — | $-0.21 | ||
| Q1 24 | — | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $20.4M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $-33.9M |
| 总资产 | $498.0M | $35.3M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPITLSI
| Q4 25 | $333.3M | $20.4M | ||
| Q3 25 | $113.9M | $22.7M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $16.5M | ||
| Q1 24 | — | $4.0M |
总债务ASPITLSI
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPITLSI
| Q4 25 | $204.2M | $-33.9M | ||
| Q3 25 | $74.1M | $-26.7M | ||
| Q2 25 | — | $-19.4M | ||
| Q1 25 | — | $-34.4M | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | $-20.4M | ||
| Q2 24 | — | $-25.3M | ||
| Q1 24 | — | $-36.0M |
总资产ASPITLSI
| Q4 25 | $498.0M | $35.3M | ||
| Q3 25 | $225.9M | $36.5M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $28.6M | ||
| Q4 24 | — | $24.0M | ||
| Q3 24 | — | $27.5M | ||
| Q2 24 | — | $32.4M | ||
| Q1 24 | — | $17.9M |
负债/权益比ASPITLSI
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-2.5M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-2.5M |
| 自由现金流率自由现金流/营收 | -284.7% | -19.1% |
| 资本支出强度资本支出/营收 | 57.9% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-19.1M |
8季度趋势，按日历期对齐
经营现金流ASPITLSI
| Q4 25 | $-37.8M | $-2.5M | ||
| Q3 25 | $-8.9M | $-3.7M | ||
| Q2 25 | — | $-7.3M | ||
| Q1 25 | — | $-4.5M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | — | $-10.8M | ||
| Q2 24 | — | $-13.4M | ||
| Q1 24 | — | $-10.9M |
自由现金流ASPITLSI
| Q4 25 | $-47.4M | $-2.5M | ||
| Q3 25 | $-12.0M | $-3.9M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | — | $-5.8M | ||
| Q3 24 | — | $-11.0M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-10.9M |
自由现金流率ASPITLSI
| Q4 25 | -284.7% | -19.1% | ||
| Q3 25 | -245.5% | -33.9% | ||
| Q2 25 | — | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | — | -69.7% | ||
| Q3 24 | — | -149.9% | ||
| Q2 24 | — | -183.1% | ||
| Q1 24 | — | -169.3% |
资本支出强度ASPITLSI
| Q4 25 | 57.9% | 0.3% | ||
| Q3 25 | 64.4% | 1.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 1.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
